Abyssinia Biologics

Abyssinia Biologics leverages its proprietary mAby antibody development platform to transform the way we treat and diagnose Alzheimer's disease and other protein aggregation disorders. Our leading preclinical candidates target soluble amyloid oligomers, including two therapeutic monoclonal antibodies, a diagnostic assay, and an epitope vaccine.